In fact, MDS patient serum increased proliferation of CD34+ cells more than control serum and this was particularly observed in patients with severe aplasia and/or anemia, where the growth stimulatory effect, although moderate, was reproducible and significant. Here, CD34 is linked to myelodysplastic syndrome.